Combining antibody conjugates with cytotoxic and immune-stimulating payloads maximizes anti-cancer activity.

Antibody-drug conjugates (ADCs) are rapidly expanding in the clinical treatment of cancers, and combinations with checkpoint inhibitors further enhance antitumor activity in patients sensitive to such immunotherapy. However, a method to improve treat…

Preview only. Read the full abstract at the source